WILKES UNIVERSITY NSG 533 ADVANCED
PHARMACOLOGY EXAM 2 – 100 PRACTICE
QUESTIONS WITH ANSWERS &
RATIONALES (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT
DOWNLOAD PDF.
CORE DOMAINS
• Pharmacokinetics and Pharmacodynamics
• Pharmacogenomics and Precision Medicine
• Pain Management and Analgesic Pharmacology
• Cardiovascular Pharmacology
• Endocrine Pharmacology
• Respiratory Pharmacology
• Gastrointestinal Pharmacology
• Antimicrobial Pharmacology
• Psychopharmacology
• Toxicology and Antidotes
INTRODUCTION
The Wilkes University NSG 533 Advanced Pharmacology Exam 2 is designed to
evaluate the graduate nursing student's mastery of pharmacological principles
essential for advanced clinical practice. This comprehensive assessment
evaluates knowledge of pharmacokinetics, pharmacodynamics,
pharmacogenomics, and therapeutic applications across major body systems,
including pain management, cardiovascular, endocrine, respiratory,
,gastrointestinal, antimicrobial, and psychopharmacological agents. The
examination employs multiple-choice and scenario-based questions that
emphasize real-world clinical application, critical thinking, and evidence-based
decision-making. It rigorously assesses the ability to integrate
pharmacogenomic data, identify drug interactions, manage adverse effects,
and apply legal and ethical prescribing standards, ensuring readiness for
autonomous advanced practice nursing roles.
SECTION ONE: QUESTIONS 1–100
1. A nurse practitioner is reviewing the pharmacokinetic profile of a
newly prescribed medication. Which of the following processes
describes the movement of a drug from its site of administration into
the bloodstream?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
C. Absorption
RATIONALE: Absorption is the pharmacokinetic process that involves the
movement of a drug from its site of administration into the bloodstream.
Distribution (A) is the movement of the drug from the bloodstream to body
tissues. Metabolism (B) is the biotransformation of the drug. Excretion (D) is
the removal of the drug from the body.
2. A patient with hepatic cirrhosis has a reduced ability to metabolize
drugs. Which pharmacokinetic process is most directly affected?
A. Absorption
B. Distribution
,C. Metabolism
D. Excretion
C. Metabolism
RATIONALE: The liver is the primary site of drug metabolism
(biotransformation). Cirrhosis impairs phase I (oxidation, reduction,
hydrolysis) and phase II (conjugation) reactions, leading to drug
accumulation and toxicity. Excretion (D) is primarily renal.
3. A drug has a half-life of 24 hours. Approximately how many hours will
it take to reach steady state if the patient takes the drug once daily?
A. 24 hours
B. 48 hours
C. 96 hours
D. 120 hours
C. 96 hours
RATIONALE: Steady state is achieved after approximately 4 to 5 half-lives.
With a 24-hour half-life, steady state occurs at 4 to 5 days (96 to 120 hours).
Once-daily dosing means steady state is reached after 4 to 5 doses, i.e., 96 to
120 hours.
4. Which of the following drug properties results in a large volume of
distribution (Vd)?
A. High water solubility
B. High protein binding
C. High lipophilicity
D. Large molecular weight
C. High lipophilicity
, RATIONALE: Lipophilic drugs cross cell membranes easily and distribute
into tissues, resulting in a large Vd (>0.6 L/kg). Water-soluble drugs remain in
the vascular space (low Vd). High protein binding (B) can limit distribution
initially.
5. A medication that acts as an antagonist at the mu-opioid receptor
will have which of the following effects?
A. Analgesia
B. Respiratory depression
C. Blockade of opioid effects
D. Euphoria
C. Blockade of opioid effects
RATIONALE: An antagonist binds to a receptor but does not activate it; it
blocks the action of agonists. Naloxone is a mu-opioid antagonist used to
reverse opioid overdose. Agonists produce analgesia (A), respiratory
depression (B), and euphoria (D).
6. A drug with zero-order kinetics:
A. Has a constant half-life regardless of dose
B. Eliminates a constant amount per unit time
C. Follows first-order elimination at high doses
D. Is never clinically relevant
B. Eliminates a constant amount per unit time
RATIONALE: Zero-order kinetics means a constant amount of drug is
eliminated per unit time (e.g., ethanol), but not at therapeutic doses. Half-life
is not constant and increases with dose. First-order kinetics eliminates a
constant fraction per time.
PHARMACOLOGY EXAM 2 – 100 PRACTICE
QUESTIONS WITH ANSWERS &
RATIONALES (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT
DOWNLOAD PDF.
CORE DOMAINS
• Pharmacokinetics and Pharmacodynamics
• Pharmacogenomics and Precision Medicine
• Pain Management and Analgesic Pharmacology
• Cardiovascular Pharmacology
• Endocrine Pharmacology
• Respiratory Pharmacology
• Gastrointestinal Pharmacology
• Antimicrobial Pharmacology
• Psychopharmacology
• Toxicology and Antidotes
INTRODUCTION
The Wilkes University NSG 533 Advanced Pharmacology Exam 2 is designed to
evaluate the graduate nursing student's mastery of pharmacological principles
essential for advanced clinical practice. This comprehensive assessment
evaluates knowledge of pharmacokinetics, pharmacodynamics,
pharmacogenomics, and therapeutic applications across major body systems,
including pain management, cardiovascular, endocrine, respiratory,
,gastrointestinal, antimicrobial, and psychopharmacological agents. The
examination employs multiple-choice and scenario-based questions that
emphasize real-world clinical application, critical thinking, and evidence-based
decision-making. It rigorously assesses the ability to integrate
pharmacogenomic data, identify drug interactions, manage adverse effects,
and apply legal and ethical prescribing standards, ensuring readiness for
autonomous advanced practice nursing roles.
SECTION ONE: QUESTIONS 1–100
1. A nurse practitioner is reviewing the pharmacokinetic profile of a
newly prescribed medication. Which of the following processes
describes the movement of a drug from its site of administration into
the bloodstream?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
C. Absorption
RATIONALE: Absorption is the pharmacokinetic process that involves the
movement of a drug from its site of administration into the bloodstream.
Distribution (A) is the movement of the drug from the bloodstream to body
tissues. Metabolism (B) is the biotransformation of the drug. Excretion (D) is
the removal of the drug from the body.
2. A patient with hepatic cirrhosis has a reduced ability to metabolize
drugs. Which pharmacokinetic process is most directly affected?
A. Absorption
B. Distribution
,C. Metabolism
D. Excretion
C. Metabolism
RATIONALE: The liver is the primary site of drug metabolism
(biotransformation). Cirrhosis impairs phase I (oxidation, reduction,
hydrolysis) and phase II (conjugation) reactions, leading to drug
accumulation and toxicity. Excretion (D) is primarily renal.
3. A drug has a half-life of 24 hours. Approximately how many hours will
it take to reach steady state if the patient takes the drug once daily?
A. 24 hours
B. 48 hours
C. 96 hours
D. 120 hours
C. 96 hours
RATIONALE: Steady state is achieved after approximately 4 to 5 half-lives.
With a 24-hour half-life, steady state occurs at 4 to 5 days (96 to 120 hours).
Once-daily dosing means steady state is reached after 4 to 5 doses, i.e., 96 to
120 hours.
4. Which of the following drug properties results in a large volume of
distribution (Vd)?
A. High water solubility
B. High protein binding
C. High lipophilicity
D. Large molecular weight
C. High lipophilicity
, RATIONALE: Lipophilic drugs cross cell membranes easily and distribute
into tissues, resulting in a large Vd (>0.6 L/kg). Water-soluble drugs remain in
the vascular space (low Vd). High protein binding (B) can limit distribution
initially.
5. A medication that acts as an antagonist at the mu-opioid receptor
will have which of the following effects?
A. Analgesia
B. Respiratory depression
C. Blockade of opioid effects
D. Euphoria
C. Blockade of opioid effects
RATIONALE: An antagonist binds to a receptor but does not activate it; it
blocks the action of agonists. Naloxone is a mu-opioid antagonist used to
reverse opioid overdose. Agonists produce analgesia (A), respiratory
depression (B), and euphoria (D).
6. A drug with zero-order kinetics:
A. Has a constant half-life regardless of dose
B. Eliminates a constant amount per unit time
C. Follows first-order elimination at high doses
D. Is never clinically relevant
B. Eliminates a constant amount per unit time
RATIONALE: Zero-order kinetics means a constant amount of drug is
eliminated per unit time (e.g., ethanol), but not at therapeutic doses. Half-life
is not constant and increases with dose. First-order kinetics eliminates a
constant fraction per time.
